HIV Disease
11
1
1
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
18.2%
2 terminated out of 11 trials
77.8%
-8.7% vs benchmark
9%
1 trials in Phase 3/4
86%
6 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (11)
The Unlocking PrEP Study: Integration of Peer Health Navigation Into Comprehensive Re-entry Services
A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects
Therapy to Elevate CD4 Counts in HIV-1 Disease
Texting to Improve Adherence in HIV+ With Bipolar Disorder
Toward Safer Opioid Prescribing for Chronic Pain in High Risk Populations
Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease
Optimizing Resilience and Coping in HIV Via Internet Delivery
Autonomic Neuropathy, GI Motility, and Inflammation in HIV
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen
Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy
Vitamin D Supplementation in HIV-infected Youth